MedTrace Logo

RT-310 Safety and Feasibility BPH Study

NCT07264205 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-20

No results posted yet for this study

Summary

RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.

Conditions

  • BPH (Benign Prostatic Hyperplasia)

Interventions

COMBINATION_PRODUCT

RT-310

RT-310

Sponsors & Collaborators

  • Resurge Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264205 on ClinicalTrials.gov